Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Conditions
Keywords
GLS-010, relapsed or refractory classic Hodgkin's lymphoma
Brief summary
The primary objective of this study is to evaluate the efficacy of GLS-010 in participants with relapsed or refractory classical Hodgkin lymphoma (R/R cHL), as measured by Progression-free Survival (PFS) as assessed by IRRC
Interventions
DRUGGLS-010
Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
DRUGChemotherapy of Investigator's choice
Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
Sponsors
Guangzhou Gloria Biosciences Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Signed written informed consent form (ICF). 2. Age of ≥ 18 years at the time of enrollment. 3. Histologically confirmed classic Hodgkin's lymphoma (cHL). 4. Subjects required Relapsed or refractory ,failure to at least 2 lines of prior systemic chemotherapy. 5. Patients who have failed prior vibutuximab treatment or are unwilling or not eligible for vibutuximab treatment 6. Have at least one measurable lesion according to Lugano classification 2014 and FDG-PET was positive. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. Life expectancy of ≥ 12 weeks. 9. Have adequate hematologic and organ function . Key
Exclusion criteria
1. Nodular lymphocytes are non-Hodgkin's lymphoma or gray area lymphoma. 2. Central nervous system lymphoma invasion. 3. Subjects requiring systemic corticosteroids or other immunosuppressive agents within 14 days prior to screening or during the study period. 4. Prior exposure to any anti-PD-1, anti-PD-L1,anti-PD-L2, anti-CD137,anti-CTLA-4 antibody, or any other antibody or drug target for T cell co-stimulatory or checkpoint pathways. 5. Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 6. Subjects with other malignancy within 5 years prior to the first dose of study treatment, except for Cervical carcinoma in situ and Cured basal cell carcinoma of the skin. 7. Have received chemotherapy, radiotherapy, molecular-targeted therapy or major surgery within 4 weeks prior to the first dose of study treatmen; Clinically significant AE associated with previous treatment has not returned to baseline or ≤1 (except hair loss). 8. Pregnant or breast-feeding women. 9. Patients are unsuitable for the study evaluated by investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) assessed by Independent Radiologic Review Committee (IRRC) per Lugano Classification 2014 | Up to 2 years | Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 2 years | Defined as the time from the date of randomization to the date of death due to any Defined as the time from the date of randomization to the date of death due to any reason |
| Objective Response Rate (ORR) | Up to 2 years | ORR defined as the proportion of subjects who achieves a best overall response of CR or PR based on Lugano 2014 classification. |
| Duration of Response (DoR) | DoR defined as the time from the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first | Up to 2 years |
| Time to Response (TTR) | TTR defined as the time from the date of randomization to the date when the response criteria are first met, based on Lugano Classification 2014 | Up to 2 years |
| Disease Control Rate (DCR) | Up to 2 years | DCR defined as the proportion of subjects' response of CR, PR, or SD based on Lugano Classification 2014. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with adverse events (AEs) | From the time of signed informed consent through 90 days after the last dose of GLS-010 | Up to 2 years |
Contacts
Primary Contactting lu
Outcome results
None listed